• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Dec. 22, 2021: TSLA, SEAC, SAVA, DCRN, METX

    12/22/21 8:52:18 AM ET
    $DCRN
    $METX
    $SAVA
    $SEAC
    Finance
    Educational Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Get the next $DCRN alert in real time by email

    Today's 5 Stock Ideas:

    • Tesla (TSLA) - A Form 4 filing from Elon Musk Tuesday evening showed the sale of Tesla stock by Musk. Investors are breathing a collective sigh of release as the disclosure of the sale reportedly marks the completion of Musk's planned stock sales.

    • SeaChange (SEAC) - The company will do a special purpose acquisition corporation (SPAC) merger with digital advertising company Triller. The new company will trader under ticker "ILLR."

    • Cassava Sciences (SAVA) - The most-searched ticker on Benzinga Pro over the last 24 hours.

    • Decarbonization Plus Acquisition Corp. II (DCRN) - A play on electric charging for boats. The company's SPAC merger partner, Tritum, Wednesday announced a deal with Aqua SuperPower boat company.

    • Meten Holding Group (METX) - A new play on crypto. The company announced Wednesday morning it established a joint venture with industry experts to create a crypto mining company.

    Get the next $DCRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DCRN
    $METX
    $SAVA
    $SEAC

    CompanyDatePrice TargetRatingAnalyst
    Tesla Inc.
    $TSLA
    3/4/2026$460.00Buy
    BofA Securities
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    Tesla Inc.
    $TSLA
    1/12/2026$120.00 → $130.00Underweight
    Wells Fargo
    Tesla Inc.
    $TSLA
    1/2/2026$444.00 → $439.00Hold
    Truist
    Tesla Inc.
    $TSLA
    12/8/2025$425.00Overweight → Equal-Weight
    Morgan Stanley
    Tesla Inc.
    $TSLA
    10/29/2025$341.00 → $471.00Neutral
    BofA Securities
    Tesla Inc.
    $TSLA
    10/23/2025$450.00 → $485.00Outperform
    Mizuho
    More analyst ratings

    $DCRN
    $METX
    $SAVA
    $SEAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on Tesla with a new price target

    BofA Securities resumed coverage of Tesla with a rating of Buy and set a new price target of $460.00

    3/4/26 8:40:18 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Tigress Financial resumed coverage on Tesla with a new price target

    Tigress Financial resumed coverage of Tesla with a rating of Buy and set a new price target of $550.00

    2/12/26 10:13:29 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Analyst reiterated coverage on Tesla with a new price target

    Analyst reiterated coverage of Tesla with a rating of Underweight and set a new price target of $145.00 from $150.00 previously

    1/30/26 8:00:23 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $DCRN
    $METX
    $SAVA
    $SEAC
    SEC Filings

    View All

    SEC Form 10-K filed by Cassava Sciences Inc.

    10-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

    3/12/26 4:01:42 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

    3/12/26 8:15:25 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

    3/10/26 8:15:27 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DCRN
    $METX
    $SAVA
    $SEAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

    New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under "FLNA" effective March 11, 2026 AUSTIN, Texas, March 10, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. ("Filana Therapeutics", or the "Company"). The new name and corporate brand reflect the Company's strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC

    3/10/26 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Announces Closure of U.S. Department of Justice Investigation

    AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.). That indictment was dismissed with prejudice by DOJ on October 23, 2025. As previously disclosed, the Company reached a settlement with the U.S. Securities an

    2/19/26 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tesla Releases Fourth Quarter and Full Year 2025 Financial Results

    Tesla has released its financial results for the fourth quarter and full year ended December 31, 2025 by posting an update on its Investor Relations website. Please visit https://ir.tesla.com to view the update. As previously announced, Tesla management will host a live question and answer (Q&A) webcast at 4:30 p.m. Central Time (5:30 p.m. Eastern Time) to discuss the results and outlook. What: Tesla Fourth Quarter and Full Year 2025 Financial Results Q&A Webcast When: Wednesday, January 28, 2026 Time: 4:30 p.m. Central Time / 5:30 p.m. Eastern Time Q4 & FY 25 Update: https://ir.tesla.com Webcast: https://ir.tesla.com (live and replay) The webcast will be archived on the company's

    1/28/26 4:07:00 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $DCRN
    $METX
    $SAVA
    $SEAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Taneja Vaibhav converted options into 6,538 shares and sold $899,077 worth of shares (2,264 units at $397.03), increasing direct ownership by 31% to 18,106 units (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    3/9/26 7:00:14 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Director Wilson-Thompson Kathleen exercised 40,000 shares at a strike of $14.99 and sold $10,692,814 worth of shares (25,731 units at $415.56), increasing direct ownership by 264% to 19,669 units (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    2/27/26 7:00:21 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    SEC Form 4 filed by SVP Zhu Xiaotong

    4 - Tesla, Inc. (0001318605) (Issuer)

    1/12/26 7:04:08 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $DCRN
    $METX
    $SAVA
    $SEAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $414,000 worth of shares (150,000 units at $2.76) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/24/25 4:02:17 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $201,809 worth of shares (73,385 units at $2.75) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/20/25 5:39:26 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DCRN
    $METX
    $SAVA
    $SEAC
    Leadership Updates

    Live Leadership Updates

    View All

    Scientists Pointing to Hidden Power Source That Could Reshape Future of AI

    This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it

    12/3/25 8:30:00 AM ET
    $AMZN
    $AVGO
    $META
    Catalog/Specialty Distribution
    Consumer Discretionary
    Semiconductors
    Technology

    Cassava Reports Q3 2025 Financials Results and Provides Business Update

    Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende

    11/12/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

    AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value creation for pre-commercial and commercial biotechnology and life science companies including Reata Pharmaceuticals, Inc. (acquired by Biogen Inc.), Geron Corporation,

    10/22/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DCRN
    $METX
    $SAVA
    $SEAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cassava Sciences Inc.

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    11/4/24 4:09:49 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Tesla Inc. (Amendment)

    SC 13G/A - Tesla, Inc. (0001318605) (Subject)

    2/14/24 4:01:18 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    SEC Form SC 13G/A filed by Cassava Sciences Inc. (Amendment)

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    2/13/24 5:01:04 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DCRN
    $METX
    $SAVA
    $SEAC
    Financials

    Live finance-specific insights

    View All

    Tesla Fourth Quarter 2025 Production, Deliveries & Deployments

    In the fourth quarter, we produced over 434,000 vehicles, delivered over 418,000 vehicles and deployed 14.2 GWh of energy storage products – a record for deployments. Thank you to all of our customers, employees, suppliers, shareholders and supporters who helped us achieve these results. Q4 2025   Production Deliveries Subject to operating lease accounting Model 3/Y 422,652 406,585 3% Other Models 11,706 11,642 5% Total 434,358 418,227 3% 2025   Production Deliveries Model 3/Y 1,600,767 1,585,279 Other Models 53,900 50,850

    1/2/26 9:07:00 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Tesla Third Quarter 2025 Production, Deliveries & Deployments

    In the third quarter, we produced over 447,000 vehicles, delivered over 497,000 vehicles and deployed 12.5 GWh of energy storage products – a record for both deliveries and deployments. Thank you to all our customers, employees, suppliers, shareholders and supporters who helped us achieve these results. Q3 2025   Production Deliveries Subject to operating lease accounting Model 3/Y 435,826 481,166 2% Other Models 11,624 15,933 7% Total 447,450 497,099 2% Tesla will post its financial results for the third quarter of 2025 after market close on Wednesday, October 22, 2025. At that ti

    10/2/25 9:04:00 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Tesla Second Quarter 2025 Production, Deliveries & Deployments

    In the second quarter, we produced over 410,000 vehicles, delivered over 384,000 vehicles and deployed 9.6 GWh of energy storage products. Thank you to all our customers, employees, suppliers, shareholders and supporters who helped us achieve these results. Q2 2025   Production Deliveries Subject to operating lease accounting Model 3/Y 396,835 373,728 2% Other Models 13,409 10,394 7% Total 410,244 384,122 2% Tesla will post its financial results for the second quarter of 2025 after market close on Wednesday, July 23, 2025. At that time, Tesla will issue a brief advisory conta

    7/2/25 9:09:00 AM ET
    $TSLA
    Auto Manufacturing
    Industrials